Spark Therapeutics (ONCE) Misses Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Spark Therapeutics Reports Second Quarter 2016 Financial Results and Recent Business Highlights
August 10, 2016 7:30 AM EDTUpdated timing of the completed BLA submission for voretigene neparvovec
Earlier today, released additional positive data from the pivotal Phase 3 trial of voretigene neparvovec
Reported positive preliminary safety and efficacy from the Phase 1/2 clinical trial of SPK-9001 in hemophilia
PHILADELPHIA, Aug. 10, 2016 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE) today announced financial results for the quarter ended June 30, 2016 and updated investors on its progress.
During the last several months, we have made significant progress advancing our clinical portfolio of AAV gene therapy... More
